> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AASLD 2026: MASH strategies split between GLP-1s and liver-fat siRNA
- URL: https://chinapharmadesk.com/aasld-2026-mash-glp1-sirna-brief-2026-11-12/
- Published: 2026-11-12T04:46:44.000Z
- Updated: 2026-11-12T08:41:28.000Z
- Description: Survodutide and semaglutide analyses probe benefit beyond weight loss; Regeneron/Alnylam’s ALN-CIDEB reports large liver-fat cuts.
- Author: LinYi
- Tags: Desk brief, Pipeline

**What moved.** Chinese industry coverage of AASLD The Liver Meeting 2026 highlighted three MASH/MASLD threads from company and meeting disclosures: Boehringer’s survodutide, Novo’s semaglutide, and Regeneron/Alnylam’s siRNA ALN-CIDEB.

**The numbers.** In a survodutide exploratory cut, among patients with <5% weight loss, 36.8% still reached MASH resolution without fibrosis worsening. A semaglutide post hoc in BMI <27 kg/m² showed liver-marker improvement versus placebo (ALT ETR 0.61). ALN-CIDEB interim data cited \~**70%** mean relative liver-fat reduction by week 12 after a single dose in some cohorts, lasting to week 24.

**Why it matters.** The competitive map is no longer “another GLP-1 for weight.” BD and portfolio teams now have to separate metabolic agonists from liver-directed genetic knockdown—and price partnering theses accordingly.

*Industry information only—not medical or investment advice.*